ATE332708T1 - Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält - Google Patents

Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält

Info

Publication number
ATE332708T1
ATE332708T1 AT01941917T AT01941917T ATE332708T1 AT E332708 T1 ATE332708 T1 AT E332708T1 AT 01941917 T AT01941917 T AT 01941917T AT 01941917 T AT01941917 T AT 01941917T AT E332708 T1 ATE332708 T1 AT E332708T1
Authority
AT
Austria
Prior art keywords
pde4 inhibitor
cancer treatment
composition containing
treatment composition
antineoplastic agent
Prior art date
Application number
AT01941917T
Other languages
English (en)
Inventor
Stephen Thomas Davis
Inderjit Kumar Dev
Ronna Ellen Dornsife
John Gordon Gray
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE332708T1 publication Critical patent/ATE332708T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01941917T 2000-06-06 2001-06-04 Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält ATE332708T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20984600P 2000-06-06 2000-06-06

Publications (1)

Publication Number Publication Date
ATE332708T1 true ATE332708T1 (de) 2006-08-15

Family

ID=22780552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941917T ATE332708T1 (de) 2000-06-06 2001-06-04 Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält

Country Status (7)

Country Link
EP (1) EP1289557B1 (de)
JP (1) JP2003535148A (de)
AT (1) ATE332708T1 (de)
AU (1) AU2001275228A1 (de)
DE (1) DE60121440T2 (de)
ES (1) ES2267778T3 (de)
WO (1) WO2001093909A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
EP3246396B1 (de) 2001-02-14 2020-01-29 Celularity, Inc. Regeneration und repopulation von dezellularisierten geweben und kadaverorganen durch stammzellen
EP2316919B1 (de) 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
EP1389468A4 (de) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co Zusammensetzungen zur förderung der knochenfrakturheilung
US7507707B2 (en) * 2001-12-14 2009-03-24 Laboratoires Serono Sa Methods of inducing ovulation using a non-polypeptide camp level modulator
JP2005522215A (ja) * 2002-04-12 2005-07-28 セルジーン・コーポレーション 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用
AU2003298775B2 (en) 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
EP1587512A2 (de) * 2003-01-14 2005-10-26 ALTANA Pharma AG Pde4 hemmer zur behandlung von neoplasmen von lymphoidzellen
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
DK1957633T3 (en) 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
EP3763376A1 (de) 2007-02-12 2021-01-13 Celularity, Inc. Behandlung von infektionskrankheiten mithilfe von plazenta-stammzellen
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
NZ599825A (en) 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
AU2009316541B2 (en) 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
LT2556145T (lt) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
ES2666746T3 (es) 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
JP6104896B2 (ja) 2011-06-01 2017-03-29 アントフロゲネシス コーポレーション 胎盤幹細胞を使用する疼痛の治療
EP2858635A1 (de) * 2012-06-11 2015-04-15 The Regents of The University of California Inhibitoren des hippo-yap-signalweges
CN115137753A (zh) 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞
US11052101B2 (en) 2019-03-25 2021-07-06 National Guard Health Affairs Methods for treating cancer using purine analogs by depleting intracellular ATP

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
CA2317093A1 (en) * 1998-01-08 1999-07-15 Joel M. Linden A2a adenosine receptor agonists
CA2325080A1 (en) * 1998-03-28 1999-10-07 The Regents Of The University Of California Dfmo and sulindac combination in cancer chemoprevention
US6399649B1 (en) * 1998-09-24 2002-06-04 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
AU2001255322A1 (en) * 2000-04-12 2001-10-30 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a topoisomerase iinhibitor
EP1188438A1 (de) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen

Also Published As

Publication number Publication date
DE60121440D1 (de) 2006-08-24
EP1289557A2 (de) 2003-03-12
JP2003535148A (ja) 2003-11-25
EP1289557B1 (de) 2006-07-12
WO2001093909A3 (en) 2002-12-05
DE60121440T2 (de) 2007-06-28
ES2267778T3 (es) 2007-03-16
WO2001093909A2 (en) 2001-12-13
AU2001275228A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
DE60121440D1 (de) Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
IL165267A (en) A drug comprising a mixture of an amino phospholipid antibody and a selected antiviral agent or antiviral vaccine conjugate, and an amino phospholipid binding antibody for use in the treatment or prevention of viral infections or diseases
EA200500234A1 (ru) Комбинированная терапия гиперпролиферативных болезней
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
PT932402E (pt) Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
WO2001051043A3 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
DE60216300D1 (de) Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
DE69940951D1 (de) Nd wachstumshemmende mittel
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
TR199901104T2 (xx) Farmas�tik bile�ikler.
TR200401669T1 (tr) Neoplastik hastalıkların tedavisi için metarix-metalloproteinazları önleyen kompozisyon.
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
BR9808221A (pt) Método de tratamento de tumor.
WO2003013554A3 (en) Aromatase inhibitors from broussonetia papyrifera
WO2002062334A3 (en) Cancer chemopreventative compounds and compositions and methods of treating cancers
PT1140115E (pt) Complexos fosfolipidicos de proantocianidin a2 como agentes anti-ateroscleroticos
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties